Index
RUT
P/E
109.49
EPS (ttm)
0.31
Insider Own
1.16%
Shs Outstand
50.62M
Perf Week
-1.29%
Market Cap
1.72B
Forward P/E
42.40
EPS next Y
0.79
Insider Trans
-13.33%
Shs Float
50.34M
Perf Month
2.49%
Enterprise Value
1.68B
PEG
0.72
EPS next Q
-0.15
Inst Own
109.32%
Perf Quarter
-17.26%
Income
16.52M
P/S
6.21
EPS this Y
35.75%
Inst Trans
-0.32%
Perf Half Y
-1.26%
Sales
276.26M
P/B
4.81
EPS next Y
82.97%
ROA
3.59%
Perf YTD
-6.41%
Book/sh
7.01
P/C
12.48
EPS next 5Y
58.82%
ROE
5.11%
52W High
45.97 -26.69%
Perf Year
-19.57%
Cash/sh
2.70
P/FCF
69.35
EPS past 3/5Y
- 39.20%
ROIC
3.76%
52W Low
28.95 16.41%
Perf 3Y
10.49%
Dividend Est.
-
EV/EBITDA
74.24
Sales past 3/5Y
18.90% 17.34%
Gross Margin
74.42%
Volatility
3.04% 4.92%
Perf 5Y
-41.67%
Dividend TTM
-
EV/Sales
6.07
EPS Y/Y TTM
57.39%
Oper. Margin
4.00%
ATR (14)
1.58
Perf 10Y
973.25%
Dividend Ex-Date
-
Quick Ratio
4.68
Sales Y/Y TTM
16.45%
Profit Margin
5.98%
RSI (14)
52.05
Dividend Gr. 3/5Y
- -
Current Ratio
5.03
EPS Q/Q
17.66%
SMA20
3.84%
Beta
1.18
Payout
0.00%
Debt/Eq
0.28
Sales Q/Q
23.27%
SMA50
-2.15%
Rel Volume
0.41
Prev Close
33.59
Employees
398
LT Debt/Eq
0.24
SMA200
-6.64%
Avg Volume
584.21K
Price
33.70
IPO
Feb 04, 1997
Option/Short
Yes / Yes
Trades
Volume
239,650
Change
0.33%
Date
Action
Analyst
Rating Change
Price Target Change
Sep-17-25 Downgrade BTIG Research
Buy → Neutral
Aug-09-24 Initiated Canaccord Genuity
Buy
$57
Jun-20-24 Initiated TD Cowen
Buy
$55
Jan-25-24 Upgrade Truist
Hold → Buy
$39 → $51
Aug-08-23 Upgrade BTIG Research
Neutral → Buy
$39
Nov-10-22 Downgrade BTIG Research
Buy → Neutral
Nov-09-22 Downgrade Truist
Buy → Hold
Oct-14-22 Resumed Stephens
Overweight
$40
Jan-11-21 Downgrade Oppenheimer
Outperform → Perform
Dec-18-20 Initiated Stephens
Overweight
$31
Sep-17-20 Initiated Truist
Buy
$24
Oct-09-19 Initiated H.C. Wainwright
Buy
$19
Feb-28-19 Downgrade Needham
Buy → Hold
Aug-08-18 Reiterated Needham
Buy
$15 → $14
Jul-16-18 Upgrade Ladenburg Thalmann
Neutral → Buy
Apr-04-18 Initiated Leerink Partners
Outperform
$15
Mar-06-18 Reiterated Needham
Buy
$5 → $15
Mar-06-18 Downgrade Ladenburg Thalmann
Buy → Neutral
Mar-05-18 Reiterated BTIG Research
Buy
$8 → $13
Jun-21-17 Initiated BTIG Research
Buy
$6
Show Previous Ratings
Apr-02-26 02:40PM
Mar-09-26 08:31PM
Mar-04-26 08:00AM
Mar-03-26 08:30AM
Feb-28-26 08:05PM
12:39PM
Loading…
Feb-27-26 12:39PM
Feb-26-26 08:09PM
04:11PM
12:15PM
07:55AM
Feb-12-26 08:30AM
Jan-13-26 12:57PM
09:00AM
Jan-06-26 08:30AM
Dec-21-25 09:57AM
08:30AM
Loading…
Nov-14-25 08:30AM
Nov-10-25 09:55AM
Nov-06-25 04:01PM
09:10AM
07:55AM
Oct-31-25 09:15AM
Oct-23-25 08:30AM
Oct-22-25 08:48AM
Oct-20-25 11:08PM
Sep-12-25 08:53AM
Sep-11-25 03:46PM
Aug-28-25 08:30AM
Aug-20-25 12:13AM
Jul-31-25 09:15AM
08:08AM
09:44AM
Loading…
Jul-30-25 09:44AM
09:00AM
Jul-24-25 09:47AM
Jul-17-25 08:30AM
Jun-10-25 08:30AM
May-09-25 03:13AM
May-08-25 09:05AM
08:45AM
07:55AM
May-07-25 02:18PM
10:08AM
08:30AM
May-06-25 05:35PM
May-01-25 05:15PM
Apr-30-25 08:39AM
Apr-24-25 08:30AM
Mar-04-25 08:30AM
Feb-28-25 02:11AM
01:51AM
(Thomson Reuters StreetEvents)
Feb-27-25 09:05AM
07:54AM
Feb-26-25 07:28AM
Feb-13-25 08:30AM
Jan-14-25 04:05PM
Jan-08-25 08:30AM
Dec-19-24 07:36AM
Nov-11-24 02:06PM
(Investor's Business Daily)
+5.15%
Nov-08-24 04:03AM
Nov-07-24 09:10AM
07:55AM
Nov-06-24 07:15AM
Oct-24-24 08:30AM
Oct-22-24 09:31AM
Oct-18-24 03:04PM
Oct-09-24 03:44PM
Aug-29-24 09:17AM
Aug-26-24 07:45AM
Aug-16-24 10:33AM
Aug-15-24 04:05PM
Aug-07-24 08:30AM
Aug-05-24 12:00PM
Aug-01-24 09:05AM
07:55AM
Jul-29-24 03:45PM
Jul-22-24 08:30AM
Jul-18-24 08:30AM
Jul-16-24 07:01PM
Jul-02-24 09:58AM
Jun-27-24 02:03PM
Jun-25-24 07:22AM
Jun-20-24 09:54AM
Jun-11-24 08:30AM
May-22-24 08:30AM
May-21-24 06:42AM
May-09-24 03:28PM
03:08AM
May-08-24 11:24PM
(Thomson Reuters StreetEvents)
09:35AM
09:10AM
07:55AM
Apr-24-24 08:30AM
Mar-29-24 07:01PM
Mar-28-24 01:48PM
(Investor's Business Daily)
Mar-15-24 07:00PM
Mar-01-24 09:30AM
Feb-29-24 11:37PM
(Thomson Reuters StreetEvents)
09:05AM
08:32AM
07:55AM
Feb-27-24 08:30AM
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Hopper Jonathan Mark Chief Medical Officer Apr 02 '26 Option Exercise 10.95 3,472 38,018 79,028 Apr 06 04:05 PM Hopper Jonathan Mark Chief Medical Officer Apr 02 '26 Sale 35.00 3,472 121,520 75,556 Apr 06 04:05 PM Hopper Jonathan Mark Officer Apr 02 '26 Proposed Sale 35.00 3,472 121,520 Apr 02 02:28 PM Rubino Alan L Director Mar 25 '26 Option Exercise 2.76 15,000 41,400 60,994 Mar 27 04:05 PM Hagen Heidi Director Mar 23 '26 Option Exercise 2.76 15,000 41,400 46,850 Mar 25 04:05 PM Hagen Heidi Director Mar 23 '26 Sale 32.41 15,000 486,150 31,850 Mar 25 04:05 PM Hagen Heidi Director Mar 23 '26 Proposed Sale 32.41 15,000 486,163 Mar 23 04:08 PM Flynn Sean C. Chief Legal Officer Mar 02 '26 Option Exercise 16.25 15,000 243,750 16,262 Mar 04 04:05 PM Flynn Sean C. Chief Legal Officer Mar 02 '26 Sale 35.18 21,421 753,530 1,262 Mar 04 04:05 PM Halpin Michael Chief Operating Officer Mar 02 '26 Sale 35.30 10,305 363,766 16,080 Mar 04 04:05 PM Flynn Sean C. Officer Mar 02 '26 Proposed Sale 35.18 21,421 753,509 Mar 02 04:54 PM Halpin Michael Officer Mar 02 '26 Proposed Sale 35.30 10,305 363,749 Mar 02 04:21 PM Colangelo Dominick President and CEO Feb 24 '26 Option Exercise 0.00 18,250 0 321,270 Feb 26 04:05 PM Hopper Jonathan Mark Chief Medical Officer Feb 24 '26 Option Exercise 0.00 4,650 0 76,192 Feb 26 04:05 PM SIEGAL JONATHAN Principal Accounting Officer Feb 24 '26 Option Exercise 0.00 3,415 0 6,585 Feb 26 04:05 PM Mara Joseph Anthony Jr Chief Financial Officer Feb 24 '26 Option Exercise 0.00 9,250 0 27,262 Feb 26 04:05 PM Halpin Michael Chief Operating Officer Feb 24 '26 Option Exercise 0.00 10,500 0 28,871 Feb 26 04:05 PM Flynn Sean C. Chief Legal Officer Feb 24 '26 Option Exercise 0.00 6,500 0 9,014 Feb 26 04:05 PM Colangelo Dominick President and CEO Feb 18 '26 Option Exercise 0.00 11,700 0 290,427 Feb 20 04:06 PM Flynn Sean C. Chief Legal Officer Feb 18 '26 Option Exercise 0.00 5,325 0 5,097 Feb 20 04:06 PM Hopper Jonathan Mark Chief Medical Officer Feb 18 '26 Option Exercise 0.00 2,325 0 72,009 Feb 20 04:06 PM Mara Joseph Anthony Jr Chief Financial Officer Feb 18 '26 Option Exercise 0.00 7,380 0 20,179 Feb 20 04:06 PM SIEGAL JONATHAN Principal Accounting Officer Feb 18 '26 Option Exercise 0.00 2,920 0 4,682 Feb 20 04:06 PM Halpin Michael Chief Operating Officer Feb 18 '26 Option Exercise 0.00 9,075 0 22,669 Feb 20 04:06 PM MCLAUGHLIN KEVIN F Director Feb 11 '26 Option Exercise 2.63 7,000 18,410 22,100 Feb 13 04:05 PM MCLAUGHLIN KEVIN F Director Feb 11 '26 Sale 34.66 7,000 242,620 15,100 Feb 13 04:05 PM MCLAUGHLIN KEVIN F Director Feb 11 '26 Proposed Sale 35.62 7,000 249,340 Feb 11 10:07 AM Halpin Michael Chief Operating Officer Jan 07 '26 Option Exercise 16.66 10,000 166,600 26,080 Jan 09 04:05 PM Halpin Michael Chief Operating Officer Jan 07 '26 Sale 40.48 10,000 404,800 16,080 Jan 09 04:05 PM Halpin Michael Officer Jan 07 '26 Proposed Sale 40.48 10,000 404,833 Jan 07 04:22 PM Mahoney Karen Chief Human Resources Officer Jul 22 '25 Option Exercise 0.00 2,625 0 2,625 Dec 12 04:05 PM Hopper Jonathan Mark Chief Medical Officer Dec 02 '25 Option Exercise 18.00 1,652 29,736 68,214 Dec 04 04:05 PM Hopper Jonathan Mark Chief Medical Officer Dec 02 '25 Sale 39.14 1,652 64,659 66,562 Dec 04 04:05 PM Wotton Paul K Director Dec 02 '25 Sale 37.97 2,500 94,925 28,102 Dec 04 04:05 PM Wotton Paul K Director Dec 03 '25 Sale 37.83 2,500 94,575 25,602 Dec 04 04:05 PM Wotton Paul K Director Dec 03 '25 Proposed Sale 37.83 2,500 94,575 Dec 03 11:25 AM Wotton Paul K Director Dec 02 '25 Proposed Sale 37.97 2,500 94,919 Dec 02 04:08 PM Hopper Jonathan Mark Officer Dec 02 '25 Proposed Sale 39.14 1,652 64,659 Dec 02 10:10 AM Halpin Michael Chief Operating Officer Nov 11 '25 Option Exercise 16.66 2,642 44,016 18,574 Nov 13 04:05 PM Halpin Michael Chief Operating Officer Nov 11 '25 Sale 40.41 2,642 106,763 15,932 Nov 13 04:05 PM MCLAUGHLIN KEVIN F Director Nov 10 '25 Option Exercise 2.63 7,000 18,410 22,100 Nov 12 04:06 PM MCLAUGHLIN KEVIN F Director Nov 10 '25 Sale 38.59 7,000 270,130 15,100 Nov 12 04:06 PM Halpin Michael Officer Nov 11 '25 Proposed Sale 40.41 2,642 106,760 Nov 12 07:33 AM Halpin Michael Chief Operating Officer Nov 06 '25 Option Exercise 16.66 7,358 122,584 23,290 Nov 10 04:05 PM Halpin Michael Chief Operating Officer Nov 06 '25 Sale 40.47 7,358 297,778 15,932 Nov 10 04:05 PM MCLAUGHLIN KEVIN F Director Nov 10 '25 Proposed Sale 39.71 7,000 277,970 Nov 10 02:47 PM Halpin Michael Officer Nov 06 '25 Proposed Sale 40.47 7,358 297,775 Nov 06 04:19 PM SIEGAL JONATHAN Principal Accounting Officer Sep 30 '25 Option Exercise 0.00 938 0 2,440 Oct 02 04:05 PM Hopper Jonathan Mark Chief Medical Officer Sep 02 '25 Option Exercise 18.00 10,000 180,000 76,363 Sep 03 04:06 PM Hopper Jonathan Mark Chief Medical Officer Sep 02 '25 Sale 35.77 10,000 357,700 66,363 Sep 03 04:06 PM Hopper Jonathan Mark Officer Sep 02 '25 Proposed Sale 35.77 10,000 357,700 Sep 02 12:14 PM MCLAUGHLIN KEVIN F Director Aug 06 '25 Option Exercise 2.76 7,000 19,320 22,100 Aug 08 04:05 PM MCLAUGHLIN KEVIN F Director Aug 06 '25 Sale 35.92 7,000 251,440 15,100 Aug 08 04:05 PM MCLAUGHLIN KEVIN F Director Aug 06 '25 Proposed Sale 35.92 7,000 251,457 Aug 06 05:18 PM Hopper Jonathan Mark Chief Medical Officer Jun 02 '25 Option Exercise 18.00 10,000 180,000 76,237 Jun 04 04:05 PM Hopper Jonathan Mark Chief Medical Officer Jun 02 '25 Sale 40.09 10,000 400,900 66,237 Jun 04 04:05 PM Hopper Jonathan Mark Officer Jun 02 '25 Proposed Sale 41.13 10,000 411,300 Jun 02 10:50 AM GILMAN STEVEN C Former Director May 30 '25 Proposed Sale 42.00 13,125 551,250 May 30 03:58 PM Colangelo Dominick President and CEO May 15 '25 Option Exercise 2.65 14,063 37,267 274,417 May 16 04:06 PM Colangelo Dominick President and CEO May 14 '25 Option Exercise 2.65 14,062 37,264 274,416 May 16 04:06 PM Colangelo Dominick President and CEO May 14 '25 Sale 42.25 14,062 594,120 260,354 May 16 04:06 PM Colangelo Dominick President and CEO May 15 '25 Sale 41.53 14,063 584,036 260,354 May 16 04:06 PM Colangelo Dominick Officer May 15 '25 Proposed Sale 42.26 14,063 594,302 May 15 10:29 AM Colangelo Dominick Officer May 14 '25 Proposed Sale 43.29 14,062 608,744 May 14 09:47 AM MCLAUGHLIN KEVIN F Director May 07 '25 Option Exercise 2.76 7,000 19,320 22,100 May 09 04:05 PM MCLAUGHLIN KEVIN F Director May 07 '25 Sale 39.98 7,000 279,860 15,100 May 09 04:05 PM MCLAUGHLIN KEVIN F Director May 07 '25 Proposed Sale 39.98 7,000 279,878 May 07 04:12 PM
